What is Wedbush’s Estimate for VYGR FY2029 Earnings?

Voyager Therapeutics, Inc. (NASDAQ:VYGR) – Equities research analysts at Wedbush issued their FY2029 earnings per share estimates for Voyager Therapeutics in a report issued on Tuesday, February 11th. Wedbush analyst Y. Zhong anticipates that the company will post earnings of ($0.86) per share for the year. Wedbush has a “Outperform” rating and a $9.00 price objective on the stock. The consensus estimate for Voyager Therapeutics’ current full-year earnings is ($0.91) per share.

Voyager Therapeutics (NASDAQ:VYGR) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.16) EPS for the quarter, beating the consensus estimate of ($0.45) by $0.29. Voyager Therapeutics had a net margin of 15.80% and a return on equity of 8.33%. The firm had revenue of $24.63 million during the quarter, compared to the consensus estimate of $12.63 million. During the same quarter in the prior year, the firm earned ($0.59) EPS.

Several other brokerages also recently weighed in on VYGR. Cantor Fitzgerald started coverage on Voyager Therapeutics in a research note on Friday, January 10th. They issued an “overweight” rating and a $5.73 target price on the stock. Canaccord Genuity Group restated a “buy” rating and issued a $14.00 price target on shares of Voyager Therapeutics in a research report on Thursday, November 14th. Leerink Partners began coverage on shares of Voyager Therapeutics in a research report on Wednesday, October 16th. They issued an “outperform” rating and a $15.00 price objective on the stock. Leerink Partnrs raised shares of Voyager Therapeutics to a “strong-buy” rating in a research note on Wednesday, October 16th. Finally, StockNews.com cut shares of Voyager Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, December 13th. One equities research analyst has rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $15.72.

Voyager Therapeutics Stock Performance

NASDAQ VYGR opened at $4.44 on Thursday. The firm’s fifty day moving average is $5.65 and its two-hundred day moving average is $6.32. Voyager Therapeutics has a one year low of $4.00 and a one year high of $10.66. The firm has a market cap of $242.56 million, a PE ratio of 6.28 and a beta of 0.91.

Institutional Trading of Voyager Therapeutics

Several large investors have recently modified their holdings of the business. Dynamic Technology Lab Private Ltd acquired a new position in Voyager Therapeutics in the fourth quarter worth about $267,000. Wells Fargo & Company MN increased its holdings in shares of Voyager Therapeutics by 3.7% in the 4th quarter. Wells Fargo & Company MN now owns 66,718 shares of the company’s stock valued at $378,000 after acquiring an additional 2,400 shares during the last quarter. ExodusPoint Capital Management LP raised its position in shares of Voyager Therapeutics by 99.5% during the 4th quarter. ExodusPoint Capital Management LP now owns 65,830 shares of the company’s stock valued at $373,000 after acquiring an additional 32,834 shares in the last quarter. Massachusetts Financial Services Co. MA raised its position in shares of Voyager Therapeutics by 8.2% during the 4th quarter. Massachusetts Financial Services Co. MA now owns 186,000 shares of the company’s stock valued at $1,055,000 after acquiring an additional 14,144 shares in the last quarter. Finally, Geode Capital Management LLC lifted its stake in Voyager Therapeutics by 0.4% during the fourth quarter. Geode Capital Management LLC now owns 1,084,238 shares of the company’s stock worth $6,149,000 after purchasing an additional 4,729 shares during the last quarter. 48.03% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Voyager Therapeutics

In related news, COO Robin Swartz sold 6,500 shares of the firm’s stock in a transaction on Monday, December 23rd. The shares were sold at an average price of $5.65, for a total transaction of $36,725.00. Following the completion of the sale, the chief operating officer now directly owns 112,328 shares of the company’s stock, valued at approximately $634,653.20. This trade represents a 5.47 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders have sold a total of 10,778 shares of company stock valued at $58,548 over the last ninety days. Corporate insiders own 4.53% of the company’s stock.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.